Barve, V.; Adams, N.; Stanbery, L.; Manning, L.; Horvath, S.; Wallraven, G.; Bognar, E.; Barve, M.; Nemunaitis, J.
Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6. Vaccines 2021, 9, 1201.
https://doi.org/10.3390/vaccines9101201
AMA Style
Barve V, Adams N, Stanbery L, Manning L, Horvath S, Wallraven G, Bognar E, Barve M, Nemunaitis J.
Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6. Vaccines. 2021; 9(10):1201.
https://doi.org/10.3390/vaccines9101201
Chicago/Turabian Style
Barve, Vedin, Ned Adams, Laura Stanbery, Luisa Manning, Staci Horvath, Gladice Wallraven, Ernest Bognar, Minal Barve, and John Nemunaitis.
2021. "Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6" Vaccines 9, no. 10: 1201.
https://doi.org/10.3390/vaccines9101201
APA Style
Barve, V., Adams, N., Stanbery, L., Manning, L., Horvath, S., Wallraven, G., Bognar, E., Barve, M., & Nemunaitis, J.
(2021). Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6. Vaccines, 9(10), 1201.
https://doi.org/10.3390/vaccines9101201